You are here: Industry Insights > Pharma in China > Second ADC Therapeutic Drug Was Approved for Marketing in China

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

3-Bromo-4-fluorobenzaldehyde

5-Methyl-1,3,4-oxadiazol2(3H)-one

4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride

4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine

3-Pyridinecarboxaldehyde

Ethyl 3 Fluorobenzoate

Second ADC Therapeutic Drug Was Approved for Marketing in China

CPhI.CNMay 14, 2020

Tag: ADC , antibody , NMPA

Favorites

By Xiaoyaowan

On May 13, the official website of NMPA showed that Takeda Pharmaceutical's application of vebutuximab for injection has been approved and became the second ADC drug approved in the Chinese market.

In 2011, vebutuximab for injection was approved by the FDA to be marketed in the United States under the trade name Adcetris. The launch of this drug created three records: The only currently marketed antibody conjugated drug targeting CD30, the first new anaplastic large cell lymphoma (ALCL) drug approved by the FDA in 40 years and the first first-line treatment for classic Hodgkin lymphoma (cHL) and peripheral T-cell lymphoma (PTCL).

Currently, vebuzumab has approved a variety of indications in the United States, including classic Hodgkin's lymphoma (cHL), anaplastic large cell lymphoma (ALCL) and peripheral T cell lymphoma (PTCL) and mycosis Granuloma (MF), etc. If you are looking for medical health supplies of vebuzumab, then Pharmasources would be your best choice.

The FDA approved a total of 6 ADC drugs for marketing. According to statistics, more than 60 ADC projects in the world have entered the stage of clinical research. The indications involved include urothelial cancer, triple negative breast cancer, HER2-positive breast cancer, glioblastoma, etc.

-----------------------------------------------------------------------
Editor's Note:

To become a freelance writer of PharmaSources.com,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@imsinoexpo.com.

Previous:Exyte and Univercells Technologies combine forces for rapid deployment of vaccine production plants

Next:India calls upon G-20 nations to ensure access to essential medicines, treatments and vaccines at af

Second ADC Therapeutic Drug Was Approved for Marketing in China

Related News

Has the booming PD-1 inhibitor reached its limit?

Future Prospects of Small Molecule and Monoclonal Antibody Drugs in Oncology and Immunology

What Sparks Will Come from the Collaboration Between CSPC and AstraZeneca?

Where Lies the Competitiveness of China's New Drugs for Central Nervous System?

You may like
More>>

Second ADC Therapeutic Drug Was Approved for Marketing in China

Related News

Has the booming PD-1 inhibitor reached its limit?

Future Prospects of Small Molecule and Monoclonal Antibody Drugs in Oncology and Immunology

What Sparks Will Come from the Collaboration Between CSPC and AstraZeneca?

Where Lies the Competitiveness of China's New Drugs for Central Nervous System?

You may likeMore>>

You may like
More>>